Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6a48134b-5b40-4f6d-a5f5-9130a469f842
Date 2/18/2014
Company Name Versartis
Mailing Address 275 Shoreline Drive Mountain View, CA 94065
Company Description Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
Proceeds Purposes The proceeds from this financing will primarily be used to prepare for an international Phase 3 pediatric GHD trial of VRS-317, the company’s proprietary long-acting rhGH for the treatment of GHD.